カテゴリー： QYResearch, 世界, 医療/バイオ

世界のTRK阻害剤市場インサイト及び予測（第一世代、第二世代）

◆英語タイトル：Global TRK Inhibitors Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09298 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：114 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥744,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,117,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,489,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、TRK阻害剤のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にTRK阻害剤の世界市場のxxx％を占める「第一世代」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「子供」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
TRK阻害剤の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのTRK阻害剤市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

TRK阻害剤のグローバル主要企業には、AstraZeneca、Aum Biosciences、Bayer、CMG Pharmaceutical、Eli Lilly & Company、InnoCare、Loxo Oncology、Ono Pharmaceutical、Pfizer、Roche、Turning Point Therapeuticsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

TRK阻害剤市場は、種類と用途によって区分されます。世界のTRK阻害剤市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
第一世代、第二世代

【用途別セグメント】
子供、成人

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- TRK阻害剤製品概要
- 種類別市場（第一世代、第二世代）
- 用途別市場（子供、成人）
- 調査の目的
・エグゼクティブサマリー
- 世界のTRK阻害剤販売量予測2017-2028
- 世界のTRK阻害剤売上予測2017-2028
- TRK阻害剤の地域別販売量
- TRK阻害剤の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別TRK阻害剤販売量
- 主要メーカー別TRK阻害剤売上
- 主要メーカー別TRK阻害剤価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（第一世代、第二世代）
- TRK阻害剤の種類別販売量
- TRK阻害剤の種類別売上
- TRK阻害剤の種類別価格
・用途別市場規模（子供、成人）
- TRK阻害剤の用途別販売量
- TRK阻害剤の用途別売上
- TRK阻害剤の用途別価格
・北米市場
- 北米のTRK阻害剤市場規模（種類別、用途別）
- 主要国別のTRK阻害剤市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのTRK阻害剤市場規模（種類別、用途別）
- 主要国別のTRK阻害剤市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のTRK阻害剤市場規模（種類別、用途別）
- 主要国別のTRK阻害剤市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のTRK阻害剤市場規模（種類別、用途別）
- 主要国別のTRK阻害剤市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのTRK阻害剤市場規模（種類別、用途別）
- 主要国別のTRK阻害剤市場規模（トルコ、サウジアラビア）
・企業情報
AstraZeneca、Aum Biosciences、Bayer、CMG Pharmaceutical、Eli Lilly & Company、InnoCare、Loxo Oncology、Ono Pharmaceutical、Pfizer、Roche、Turning Point Therapeutics
・産業チェーン及び販売チャネル分析
- TRK阻害剤の産業チェーン分析
- TRK阻害剤の原材料
- TRK阻害剤の生産プロセス
- TRK阻害剤の販売及びマーケティング
- TRK阻害剤の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- TRK阻害剤の産業動向
- TRK阻害剤のマーケットドライバー
- TRK阻害剤の課題
- TRK阻害剤の阻害要因
・主な調査結果

Market Analysis and Insights: Global TRK Inhibitors Market
The global TRK Inhibitors market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, First-generation accounting for % of the TRK Inhibitors global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Child segment is altered to an % CAGR throughout this forecast period.
China TRK Inhibitors market size is valued at US$ million in 2021, while the North America and Europe TRK Inhibitors are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe TRK Inhibitors landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global TRK Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global TRK Inhibitors market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global TRK Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global TRK Inhibitors market.
Global TRK Inhibitors Scope and Market Size
TRK Inhibitors market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global TRK Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
First-generation
Second-generation
Segment by Application
Child
Aldult
By Company
AstraZeneca
Aum Biosciences
Bayer
CMG Pharmaceutical
Eli Lilly & Company
InnoCare
Loxo Oncology
Ono Pharmaceutical
Pfizer
Roche
Turning Point Therapeutics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global TRK Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 First-generation
1.2.3 Second-generation
1.3 Market by Application
1.3.1 Global TRK Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Child
1.3.3 Aldult
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global TRK Inhibitors Market Perspective (2017-2028)
2.2 TRK Inhibitors Growth Trends by Region
2.2.1 TRK Inhibitors Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 TRK Inhibitors Historic Market Size by Region (2017-2022)
2.2.3 TRK Inhibitors Forecasted Market Size by Region (2023-2028)
2.3 TRK Inhibitors Market Dynamics
2.3.1 TRK Inhibitors Industry Trends
2.3.2 TRK Inhibitors Market Drivers
2.3.3 TRK Inhibitors Market Challenges
2.3.4 TRK Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top TRK Inhibitors Players by Revenue
3.1.1 Global Top TRK Inhibitors Players by Revenue (2017-2022)
3.1.2 Global TRK Inhibitors Revenue Market Share by Players (2017-2022)
3.2 Global TRK Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by TRK Inhibitors Revenue
3.4 Global TRK Inhibitors Market Concentration Ratio
3.4.1 Global TRK Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by TRK Inhibitors Revenue in 2021
3.5 TRK Inhibitors Key Players Head office and Area Served
3.6 Key Players TRK Inhibitors Product Solution and Service
3.7 Date of Enter into TRK Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 TRK Inhibitors Breakdown Data by Type
4.1 Global TRK Inhibitors Historic Market Size by Type (2017-2022)
4.2 Global TRK Inhibitors Forecasted Market Size by Type (2023-2028)
5 TRK Inhibitors Breakdown Data by Application
5.1 Global TRK Inhibitors Historic Market Size by Application (2017-2022)
5.2 Global TRK Inhibitors Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America TRK Inhibitors Market Size (2017-2028)
6.2 North America TRK Inhibitors Market Size by Type
6.2.1 North America TRK Inhibitors Market Size by Type (2017-2022)
6.2.2 North America TRK Inhibitors Market Size by Type (2023-2028)
6.2.3 North America TRK Inhibitors Market Share by Type (2017-2028)
6.3 North America TRK Inhibitors Market Size by Application
6.3.1 North America TRK Inhibitors Market Size by Application (2017-2022)
6.3.2 North America TRK Inhibitors Market Size by Application (2023-2028)
6.3.3 North America TRK Inhibitors Market Share by Application (2017-2028)
6.4 North America TRK Inhibitors Market Size by Country
6.4.1 North America TRK Inhibitors Market Size by Country (2017-2022)
6.4.2 North America TRK Inhibitors Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe TRK Inhibitors Market Size (2017-2028)
7.2 Europe TRK Inhibitors Market Size by Type
7.2.1 Europe TRK Inhibitors Market Size by Type (2017-2022)
7.2.2 Europe TRK Inhibitors Market Size by Type (2023-2028)
7.2.3 Europe TRK Inhibitors Market Share by Type (2017-2028)
7.3 Europe TRK Inhibitors Market Size by Application
7.3.1 Europe TRK Inhibitors Market Size by Application (2017-2022)
7.3.2 Europe TRK Inhibitors Market Size by Application (2023-2028)
7.3.3 Europe TRK Inhibitors Market Share by Application (2017-2028)
7.4 Europe TRK Inhibitors Market Size by Country
7.4.1 Europe TRK Inhibitors Market Size by Country (2017-2022)
7.4.2 Europe TRK Inhibitors Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific TRK Inhibitors Market Size (2017-2028)
8.2 Asia-Pacific TRK Inhibitors Market Size by Type
8.2.1 Asia-Pacific TRK Inhibitors Market Size by Type (2017-2022)
8.2.2 Asia-Pacific TRK Inhibitors Market Size by Type (2023-2028)
8.2.3 Asia-Pacific TRK Inhibitors Market Share by Type (2017-2028)
8.3 Asia-Pacific TRK Inhibitors Market Size by Application
8.3.1 Asia-Pacific TRK Inhibitors Market Size by Application (2017-2022)
8.3.2 Asia-Pacific TRK Inhibitors Market Size by Application (2023-2028)
8.3.3 Asia-Pacific TRK Inhibitors Market Share by Application (2017-2028)
8.4 Asia-Pacific TRK Inhibitors Market Size by Region
8.4.1 Asia-Pacific TRK Inhibitors Market Size by Region (2017-2022)
8.4.2 Asia-Pacific TRK Inhibitors Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America TRK Inhibitors Market Size (2017-2028)
9.2 Latin America TRK Inhibitors Market Size by Type
9.2.1 Latin America TRK Inhibitors Market Size by Type (2017-2022)
9.2.2 Latin America TRK Inhibitors Market Size by Type (2023-2028)
9.2.3 Latin America TRK Inhibitors Market Share by Type (2017-2028)
9.3 Latin America TRK Inhibitors Market Size by Application
9.3.1 Latin America TRK Inhibitors Market Size by Application (2017-2022)
9.3.2 Latin America TRK Inhibitors Market Size by Application (2023-2028)
9.3.3 Latin America TRK Inhibitors Market Share by Application (2017-2028)
9.4 Latin America TRK Inhibitors Market Size by Country
9.4.1 Latin America TRK Inhibitors Market Size by Country (2017-2022)
9.4.2 Latin America TRK Inhibitors Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa TRK Inhibitors Market Size (2017-2028)
10.2 Middle East & Africa TRK Inhibitors Market Size by Type
10.2.1 Middle East & Africa TRK Inhibitors Market Size by Type (2017-2022)
10.2.2 Middle East & Africa TRK Inhibitors Market Size by Type (2023-2028)
10.2.3 Middle East & Africa TRK Inhibitors Market Share by Type (2017-2028)
10.3 Middle East & Africa TRK Inhibitors Market Size by Application
10.3.1 Middle East & Africa TRK Inhibitors Market Size by Application (2017-2022)
10.3.2 Middle East & Africa TRK Inhibitors Market Size by Application (2023-2028)
10.3.3 Middle East & Africa TRK Inhibitors Market Share by Application (2017-2028)
10.4 Middle East & Africa TRK Inhibitors Market Size by Country
10.4.1 Middle East & Africa TRK Inhibitors Market Size by Country (2017-2022)
10.4.2 Middle East & Africa TRK Inhibitors Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca TRK Inhibitors Introduction
11.1.4 AstraZeneca Revenue in TRK Inhibitors Business (2017-2022)
11.1.5 AstraZeneca Recent Developments
11.2 Aum Biosciences
11.2.1 Aum Biosciences Company Details
11.2.2 Aum Biosciences Business Overview
11.2.3 Aum Biosciences TRK Inhibitors Introduction
11.2.4 Aum Biosciences Revenue in TRK Inhibitors Business (2017-2022)
11.2.5 Aum Biosciences Recent Developments
11.3 Bayer
11.3.1 Bayer Company Details
11.3.2 Bayer Business Overview
11.3.3 Bayer TRK Inhibitors Introduction
11.3.4 Bayer Revenue in TRK Inhibitors Business (2017-2022)
11.3.5 Bayer Recent Developments
11.4 CMG Pharmaceutical
11.4.1 CMG Pharmaceutical Company Details
11.4.2 CMG Pharmaceutical Business Overview
11.4.3 CMG Pharmaceutical TRK Inhibitors Introduction
11.4.4 CMG Pharmaceutical Revenue in TRK Inhibitors Business (2017-2022)
11.4.5 CMG Pharmaceutical Recent Developments
11.5 Eli Lilly & Company
11.5.1 Eli Lilly & Company Company Details
11.5.2 Eli Lilly & Company Business Overview
11.5.3 Eli Lilly & Company TRK Inhibitors Introduction
11.5.4 Eli Lilly & Company Revenue in TRK Inhibitors Business (2017-2022)
11.5.5 Eli Lilly & Company Recent Developments
11.6 InnoCare
11.6.1 InnoCare Company Details
11.6.2 InnoCare Business Overview
11.6.3 InnoCare TRK Inhibitors Introduction
11.6.4 InnoCare Revenue in TRK Inhibitors Business (2017-2022)
11.6.5 InnoCare Recent Developments
11.7 Loxo Oncology
11.7.1 Loxo Oncology Company Details
11.7.2 Loxo Oncology Business Overview
11.7.3 Loxo Oncology TRK Inhibitors Introduction
11.7.4 Loxo Oncology Revenue in TRK Inhibitors Business (2017-2022)
11.7.5 Loxo Oncology Recent Developments
11.8 Ono Pharmaceutical
11.8.1 Ono Pharmaceutical Company Details
11.8.2 Ono Pharmaceutical Business Overview
11.8.3 Ono Pharmaceutical TRK Inhibitors Introduction
11.8.4 Ono Pharmaceutical Revenue in TRK Inhibitors Business (2017-2022)
11.8.5 Ono Pharmaceutical Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Details
11.9.2 Pfizer Business Overview
11.9.3 Pfizer TRK Inhibitors Introduction
11.9.4 Pfizer Revenue in TRK Inhibitors Business (2017-2022)
11.9.5 Pfizer Recent Developments
11.10 Roche
11.10.1 Roche Company Details
11.10.2 Roche Business Overview
11.10.3 Roche TRK Inhibitors Introduction
11.10.4 Roche Revenue in TRK Inhibitors Business (2017-2022)
11.10.5 Roche Recent Developments
11.11 Turning Point Therapeutics
11.11.1 Turning Point Therapeutics Company Details
11.11.2 Turning Point Therapeutics Business Overview
11.11.3 Turning Point Therapeutics TRK Inhibitors Introduction
11.11.4 Turning Point Therapeutics Revenue in TRK Inhibitors Business (2017-2022)
11.11.5 Turning Point Therapeutics Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のTRK阻害剤市場インサイト及び予測（第一世代、第二世代）(Global TRK Inhibitors Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界のTRK阻害剤市場インサイト及び予測（第一世代、第二世代）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp